175 related articles for article (PubMed ID: 23031302)
21. Infliximab, as sole or combined therapy, induces rapid clearing of erythrodermic psoriasis.
Takahashi MD; Castro LG; Romiti R
Br J Dermatol; 2007 Oct; 157(4):828-31. PubMed ID: 17711530
[No Abstract] [Full Text] [Related]
22. Review and expert opinion on prevention and treatment of infliximab-related infusion reactions.
Lecluse LL; Piskin G; Mekkes JR; Bos JD; de Rie MA
Br J Dermatol; 2008 Sep; 159(3):527-36. PubMed ID: 18627374
[TBL] [Abstract][Full Text] [Related]
23. Autoimmune hepatitis associated with infliximab in a patient with palmoplantar pustular psoriaisis.
Fairhurst DA; Sheehan-Dare R
Clin Exp Dermatol; 2009 Apr; 34(3):421-2. PubMed ID: 19309375
[No Abstract] [Full Text] [Related]
24. Fatal influenza A(H1N1) respiratory tract infection in a patient having psoriasis treated with infliximab.
Kling MC; Larian AA; Scordi-Bello I; Emer J; Lebwohl MG
Arch Dermatol; 2010 Jun; 146(6):651-4. PubMed ID: 20566928
[TBL] [Abstract][Full Text] [Related]
25. Improvement in quality of life with infliximab induction and maintenance therapy in patients with moderate-to-severe psoriasis: a randomized controlled trial.
Reich K; Nestle FO; Papp K; Ortonne JP; Wu Y; Bala M; Evans R; Guzzo C; Li S; Dooley LT; Griffiths CE
Br J Dermatol; 2006 Jun; 154(6):1161-8. PubMed ID: 16704649
[TBL] [Abstract][Full Text] [Related]
26. Lewis-Sumner syndrome associated with infliximab therapy for psoriasis.
Oliveira KF; Martins GA; Galvão KR; Kurizky PS
An Bras Dermatol; 2017; 92(1):156-157. PubMed ID: 28225983
[No Abstract] [Full Text] [Related]
27. Evaluation of the efficacy and safety of infliximab on psoriatic nails: an unblinded, nonrandomized, open-label study.
Rigopoulos D; Gregoriou S; Stratigos A; Larios G; Korfitis C; Papaioannou D; Antoniou C; Ioannides D
Br J Dermatol; 2008 Aug; 159(2):453-6. PubMed ID: 18565184
[TBL] [Abstract][Full Text] [Related]
28. Treatment of recalcitrant pustular psoriasis with infliximab: effective reduction of chemokine expression.
Benoit S; Toksoy A; Bröcker EB; Gillitzer R; Goebeler M
Br J Dermatol; 2004 May; 150(5):1009-12. PubMed ID: 15149518
[TBL] [Abstract][Full Text] [Related]
29. Acute alveolitis following infliximab therapy for psoriasis.
Bale J; Chee P
Australas J Dermatol; 2013 Feb; 54(1):61-3. PubMed ID: 22780696
[TBL] [Abstract][Full Text] [Related]
30. Hepatitis: a rare, but important, complication of infliximab therapy for psoriasis.
Wahie S; Alexandroff A; Reynolds NJ
Clin Exp Dermatol; 2006 May; 31(3):460-1. PubMed ID: 16681606
[No Abstract] [Full Text] [Related]
31. Infliximab for psoriasis.
Gottlieb AB
J Am Acad Dermatol; 2003 Aug; 49(2 Suppl):S112-7. PubMed ID: 12894134
[TBL] [Abstract][Full Text] [Related]
32. Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial.
Gottlieb AB; Evans R; Li S; Dooley LT; Guzzo CA; Baker D; Bala M; Marano CW; Menter A
J Am Acad Dermatol; 2004 Oct; 51(4):534-42. PubMed ID: 15389187
[TBL] [Abstract][Full Text] [Related]
33. An open-label pilot study of infliximab therapy in diffuse cutaneous systemic sclerosis.
Denton CP; Engelhart M; Tvede N; Wilson H; Khan K; Shiwen X; Carreira PE; Diaz Gonzalez F; Black CM; van den Hoogen FH
Ann Rheum Dis; 2009 Sep; 68(9):1433-9. PubMed ID: 18782794
[TBL] [Abstract][Full Text] [Related]
34. Infliximab treatment results in significant improvement in the quality of life of patients with severe psoriasis: a double-blind placebo-controlled trial.
Feldman SR; Gordon KB; Bala M; Evans R; Li S; Dooley LT; Guzzo C; Patel K; Menter A; Gottlieb AB
Br J Dermatol; 2005 May; 152(5):954-60. PubMed ID: 15888152
[TBL] [Abstract][Full Text] [Related]
35. Disseminated systemic Nocardia farcinica infection complicating alefacept and infliximab therapy in a patient with severe psoriasis.
Al-Tawfiq JA; Al-Khatti AA
Int J Infect Dis; 2010 Feb; 14(2):e153-7. PubMed ID: 19501534
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of infliximab vs. methotrexate in patients with moderate-to-severe plaque psoriasis: results of an open-label, active-controlled, randomized trial (RESTORE1).
Barker J; Hoffmann M; Wozel G; Ortonne JP; Zheng H; van Hoogstraten H; Reich K
Br J Dermatol; 2011 Nov; 165(5):1109-17. PubMed ID: 21910713
[TBL] [Abstract][Full Text] [Related]
37. Infliximab for the treatment of adults with psoriasis.
Loveman E; Turner D; Hartwell D; Cooper K; Clegg A
Health Technol Assess; 2009 Jun; 13 Suppl 1():55-60. PubMed ID: 19567215
[TBL] [Abstract][Full Text] [Related]
38. Response of severe psoriasis to infliximab.
Mang R; Stege H; Ruzicka T; Krutmann J
Dermatology; 2002; 204(2):156-7. PubMed ID: 11937748
[No Abstract] [Full Text] [Related]
39. [Body-weight changes in psoriatic patients on systemic treatment].
Forien M; Mahé E; Sin C; Marchal A; Sigal ML
Ann Dermatol Venereol; 2012 Oct; 139(10):649-51. PubMed ID: 23122380
[No Abstract] [Full Text] [Related]
40. Tumor necrosis factor (TNF) inhibitors revolutionalized therapy for both psoriasis and psoriatic arthritis. Foreword.
Gottlieb AB
Am J Clin Dermatol; 2014 Feb; 15 Suppl 1():S3-4. PubMed ID: 24777570
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
